However, the expressions of PD-L2 and some novel checkpoint genes were upregulated in the high-risk group, and studies have uncovered that PD-L2 leads to immune suppression and a poor prognosis in gastric cancer patients [29,30,31]; this may be the underlying immunotherapeutic target of our model. Here, PDCD1LG2 is linked to gastric cancer.